NEW YORK (GenomeWeb News) – Affymetrix reported after the close of the market Wednesday that its second-quarter revenues declined 6 percent year-over-year while a loss in the year-ago period swung to a $7.3 million profit.

Affy posted total second-quarter revenue of $81.6 million, compared to $86.9 million in the comparable period of 2008. The company reported a negative currency impact of $3 million.

Its results handily beat analysts' consensus estimate of $77.1 million. In early Thursday trade on the Nasdaq, Affy's shares soared 24 percent to $7.28.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.

Sponsored by
Dovetail Genomics

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research. 

Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

Sponsored by
Dovetail Genomics

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.